B. Guy-Grand (2004
|
randomized, double-blind placebo-controlled parallel-group clinical
trial
|
120 mg(tid)
placebo
|
6
|
M/F
|
458/458
|
18–65
|
mildly reduced-calorie diet
|
obese patients (BMI 28–40 kg/m2)
untreated type 2 diabetes
untreated hypertension hypercholesterolemia
|
T. P. Didangelos (2004)
|
randomized open-label prospective multicenter parallel-group controlled
clinical trial
|
360 mg/day
control
|
6
|
M/F
|
94/32
|
30–72
|
hypocaloric diet (HCD)
(500 calories below the needs(mean daily calorie intake 1300)
|
type 2 DM treated with oral antidiabetic agents (metformin alone or in
combination with sulfonylureas) All patients had the MetSyn
|
Giuseppe Cocco (2005)
|
randomized double blind placebo-controlled parallel-group clinical
trial
|
120 mg(tid)
placebo
|
6
|
M/F
|
45/45
|
at least 35
|
standardized physical program(walk briskly for at least 30 min per day)
+fat-restricted diet
|
adipose patients (BMI 31-40kg/m2)
metabolic syndrome,diabetes type 2
hypertension treated with drug coronary heart disease concomitant
cardiac dysfunction Antidiabetic drugs
|
T. D. Filippatos (2005)
|
randomized open-label parallel-group clinical trial
|
120 mg(tid)
control
|
3
|
M/F
|
28/29
|
53 ± 11
|
micronised fenofibrate 200 mg/day + low-calorie low-fat diet (500–1000
kcal reduction in daily energy)
|
Overweight and obese (BMI > 28 kg/m2) ,MetS
|
E. S. Nakou (2008)
|
randomized open-label parallel-group clinical trial
|
120 mg(tid)
control
|
6
|
M/F
|
29/28
|
55 ± 10
|
ezetimibe 10 mg/day+
low-fat low-calorie diet
|
BMI>28 kg/m2
hypercholesterolemia antihypertensive drugs
on a stabilised dose for at least 8 weeks before entry to the
study
|
Jinghua Song (2018)
|
randomized open-label parallel-group clinical trial
|
120 mg(tid)
control
|
3
|
F
|
60/60
|
18–40
|
Diane-35+individualized low-fat diet and moderate daily physical
activity
|
PCOS
BMI> 24 kg/m2
|
|
|
120 mg(tid)
control
|
|
F
|
60/60
|
|
metformin(500mg/day for the first week/500mg twice daily for the next
week) +Diane-35 (OMD group)+ individualized low-fat diet and moderate
daily physical activity
|
|
Junzhao Ye (2019)
|
randomized open-label parallel-group clinical trial
|
120 mg(tid)
control
|
6
|
M/F
|
ITT
68/102
|
18 - 60
|
without additional
treatment
|
Obese BMI> 25 kg/m2 NAFLD
no history of use of medication associated with obesity
|
|
|
120 mg(tid)
control
|
|
M/F
|
PPA
54/76
|
|
|
|